

PATENT

Attorney Docket No. VACCINE-10801

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David R. Milich *et al.*  
Serial No.: 10/566,322  
Filed: 01/26/2006  
For: **Hepatitis Virus Core Proteins As Vaccine Platforms And Methods  
Of Use Thereof**

Group No.:  
Examiner:

## TRANSMITTAL

## MS PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 15, 2007

By: 

Cliff Cannon-Cin

Dear Sir or Madam:

In response to the Notification of Missing Requirements under 35 U.S.C. 371 mailed  
**August 14, 2007** (a copy of which is enclosed), Applicants submit the following documents:

- combined Declaration and Power of Attorney;
- Power of Attorney by Assignee, an Assignment document was submitted for recordation by facsimile, whereby the subject application and the invention disclosed therein is assigned to the Vaccine Research Institute of San Diego, 3030 Bunker Hill Street, Suite 300, San Diego, California, 92109;
- Sequence Listing on a computer-readable diskette;
- Certificate re: Sequence Listing; and
- Information Disclosure Statement with PTO FORM-1449.

A check in the amount of **\$65.00** is enclosed herewith to cover the surcharge for filing missing parts of an application.


10/19/2007 LLANDGRA 00000051 10566322

01 FC:2617

65.00 0P

In addition, the Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. **08-1290**. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Dated: October 15, 2007

By:   
Christine A. Lekutis  
Registration No. 51,934

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
(415) 904-6500




## UNITED STATES PATENT AND TRADEMARK OFFICE

SF

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/566,322	David R. MILICH	VACCINE-10801

Christine A Lekutis  
 MEDLEN & CARROLL  
 Suite 350  
 101 Howard Street  
 San Francisco, CA 94105



INTERNATIONAL APPLICATION NO.	
PCT/US04/23391	
I.A. FILING DATE	PRIORITY DATE
07/19/2004	07/30/2003

CONFIRMATION NO. 3500  
 371 FORMALITIES LETTER



\*OC000000025348341\*

Date Mailed: 08/14/2007

*Resp. 10/14/07 rev*

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 01/26/2006
- Copy of the International Search Report filed on 01/26/2006
- Preliminary Amendments filed on 01/26/2006
- Oath or Declaration filed on 01/26/2006
- Biochemical Sequence Listing filed on 01/26/2006
- Request for Immediate Examination filed on 01/26/2006
- U.S. Basic National Fees filed on 01/26/2006
- Priority Documents filed on 01/26/2006
- Specification filed on 01/26/2006
- Claims filed on 01/26/2006
- Abstracts filed on 01/26/2006
- Drawings filed on 01/26/2006
- Paper nucleotide sequence listings filed on 01/26/2006

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
  - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.

- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.

#### SUMMARY OF FEES DUE:

Total additional fees required for this application is \$65 for a Small Entity:

- **\$65 Surcharge.**
  - This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.

<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

SHAKEEL AHMED

Telephone: (703) 308-9140 EXT 208

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/566,322	PCT/US04/23391	VACCINE-10801

FORM PCT/DO/EO/905 (371 Formalities Notice)